Open clinical trial data for all? a view from regulators

PLoS Medicine

Volumn 9, Issue 4, 2012, Pages

  Eichler, Hans Georg ^a   Abadie, Eric ^a,b   Breckenridge, Alasdair ^c   Leufkens, Hubert ^a,d   Rasi, Guido ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b AFSSAPS   (France)

^c MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^d MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; CLINICAL STUDY; HUMAN; INFORMATION PROCESSING; PATIENT POSITIONING; PUBLIC HEALTH; DRUG INDUSTRY; INFORMATION DISSEMINATION; LITERATURE; NOTE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

OSELTAMIVIR;

DRUG INDUSTRY; HUMANS; INFORMATION DISSEMINATION; OSELTAMIVIR; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 84860142228     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001202     Document Type: Article

References (11)

1. Doshi P, Jefferson T, del Mar C, (2012) The imperative to share clinical study reports. PLoS Med 9.
2. Hrynaszkiewicz I, Altman DG, (2009) Towards agreement on best practice for publishing raw clinical trial data. Trials 10: 17 Available: http://www.trialsjournal.com/content/10/1/17. Accessed 9 March 2012.
3. Selker HP, Ruthazer R, Terrin N, Griffith JL, Concannon T, et al. (2011) Random treatment assignment using mathematical equipoise for comparative effectiveness trials. Clin Transl Sci 4 (1): 10-16.
4. Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, et al. (2002) An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 113 (2): 104-111.
5. Nielsen M, (2012) Reinventing discovery: the new era of networked science Princeton and Oxford Princeton University Press.
6. Poland GA, Jacobson RM, (2011) The age-old struggle against the antivaccinationists. N Engl J Med 364: 97-99.
7. Lofstedt R, Bouder F, Chakraborty S, (2012) Transparency and the FDA - a quantitative study. J Health Communications In press.
8. Michele TM, Pinheiro S, Iyasu S, (2010) The safety of tiotropium - the FDA's conclusions. N Engl J Med 363: 1097-1099.
9. European Medicines Agency (2011) Questions and answers on the review of angiotensin II receptor antagonists and the risk of cancer. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2011/10/WC500116862.pdf. Accessed 9 March 2012.
10. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (2011) The ENCePP Code of Conduct for Scientific Independence and Transparency in the Conduct of Pharmacoepidemiological and Pharmacovigilance Studies. Available: http://www.encepp.eu/code_of_conduct/documents/CodeofConduct_Rev2.pdf. Accessed 9 March 2012.
11. Young SS, Karr A, (2011) Deming, data and observational studies. Significance 8 (3): 116-120.